Peel Hunt Reaffirms “Buy” Rating for Shield Therapeutics (LON:STX)

Shield Therapeutics (LON:STX)‘s stock had its “buy” rating restated by analysts at Peel Hunt in a research report issued on Wednesday, Marketbeat.com reports. They currently have a GBX 15 price objective on the stock. Peel Hunt’s target price suggests a potential upside of 89.87% from the company’s previous close.

Shield Therapeutics Price Performance

Shares of STX opened at GBX 7.90 on Wednesday. The firm has a market cap of £82.29 million, a price-to-earnings ratio of -395.00 and a beta of 1.42. The stock has a 50 day moving average of GBX 6.67 and a 200-day moving average of GBX 4.09. The company has a current ratio of 1.05, a quick ratio of 2.16 and a debt-to-equity ratio of 3,691.50. Shield Therapeutics has a 52 week low of GBX 2.10 and a 52 week high of GBX 9.10.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.